Catherine Leger

529 total citations · 1 hit paper
10 papers, 263 citations indexed

About

Catherine Leger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Catherine Leger has authored 10 papers receiving a total of 263 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Catherine Leger's work include Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (6 papers) and Gastric Cancer Management and Outcomes (4 papers). Catherine Leger is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (6 papers) and Gastric Cancer Management and Outcomes (4 papers). Catherine Leger collaborates with scholars based in France, Spain and Italy. Catherine Leger's co-authors include Nadia Amellal, Josep Tabernero, Julien Taı̈eb, Gerald W. Prager, Eric Van Cutsem, Marwan Fakih, Fortunato Ciardiello, Chiara Cremolini, Élena Elez and Dominik Paul Modest and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and European Journal of Cancer.

In The Last Decade

Catherine Leger

9 papers receiving 257 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

2023 183 citations Gerald W. Prager, Julien Taı̈eb et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catherine Leger France	5	216	96	77	39	33	10	263
Pierre-Guillaume Poureau France	5	219 1.0×	93 1.0×	72 0.9×	40 1.0×	33 1.0×	12	272
Merete Krogh Denmark	6	195 0.9×	70 0.7×	43 0.6×	32 0.8×	21 0.6×	17	233
Loïck Vidot France	5	224 1.0×	78 0.8×	85 1.1×	37 0.9×	29 0.9×	13	273
Erica N. Heying United States	6	223 1.0×	86 0.9×	92 1.2×	24 0.6×	42 1.3×	10	285
Patrick Texereau France	8	221 1.0×	93 1.0×	50 0.6×	25 0.6×	40 1.2×	15	280
Rosa Rita Silva Italy	8	189 0.9×	86 0.9×	47 0.6×	66 1.7×	51 1.5×	18	253
Dong Ma China	5	193 0.9×	78 0.8×	58 0.8×	63 1.6×	26 0.8×	13	284
T.W. Kim South Korea	8	226 1.0×	93 1.0×	60 0.8×	32 0.8×	38 1.2×	26	264
M. Frueh Switzerland	9	258 1.2×	189 2.0×	20 0.3×	41 1.1×	43 1.3×	31	322
Dario Nicolella Italy	9	227 1.1×	158 1.6×	37 0.5×	108 2.8×	45 1.4×	16	332

Countries citing papers authored by Catherine Leger

Since Specialization

Citations

This map shows the geographic impact of Catherine Leger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Leger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Leger more than expected).

Fields of papers citing papers by Catherine Leger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Leger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Leger. The network helps show where Catherine Leger may publish in the future.

Co-authorship network of co-authors of Catherine Leger

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Leger. A scholar is included among the top collaborators of Catherine Leger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Leger. Catherine Leger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Prager, Gerald W., Julien Taı̈eb, Marwan Fakih, et al.. (2023). Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. New England Journal of Medicine. 388(18). 1657–1667. 183 indexed citations breakdown →

Tabernero, Josep, Gerald W. Prager, Marwan Fakih, et al.. (2023). Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.. Journal of Clinical Oncology. 41(4_suppl). 4–4. 27 indexed citations

Tabernero, Josep, Julien Taı̈eb, Gerald W. Prager, et al.. (2021). Trifluridine/Tipiracil Plus Bevacizumab for Third-Line Management of Metastatic Colorectal Cancer: SUNLIGHT Study Design. Future Oncology. 17(16). 1977–1985. 32 indexed citations

Bordonaro, Roberto, Aitana Calvo, A. Auriemma, et al.. (2020). Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab: Results of the expansion part of a phase I study in patients with metastatic colorectal cancer.. Journal of Clinical Oncology. 38(4_suppl). 140–140. 1 indexed citations

Argilés, Guillem, Thierry André, Antoine Hollebecque, et al.. (2019). Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. European Journal of Cancer. 112. 12–19. 8 indexed citations

Alsina, María, Josep Tabernero, Kohei Shitara, et al.. (2019). Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).. Journal of Clinical Oncology. 37(15_suppl). 4043–4043. 4 indexed citations

Hollebecque, Antoine, Aitana Calvo, Thierry André, et al.. (2018). Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 36(4_suppl). 816–816. 4 indexed citations

Hollebecque, Antoine, Guillem Argilés, Thierry André, et al.. (2017). A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer.. Journal of Clinical Oncology. 35(15_suppl). TPS3626–TPS3626. 2 indexed citations

Cutsem, Eric Van, Atsushi Ohtsu, Catherine Leger, et al.. (2017). Effect of number of prior lines versus prior regimens in pts receiving trifluridine/tipiracil (TAS-102).. Journal of Clinical Oncology. 35(4_suppl). 720–720. 1 indexed citations

10.

Leger, Catherine. (1996). Dynasties d’entreprise et dynasties d’entreprendre. Entreprises et histoire. n° 12(2). 89–100. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact